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OBJECTIVE — To examine the association between levels of hyperglycemia, determined by
each prenatal oral glucose tolerance test (OGTT) value (fasting, 1 and 2 h), and maternal and
perinatal outcomes and to determine whether the risk for these outcomes differs for women
whose value(s) equaled or exceeded the thresholds for gestational diabetes mellitus (GDM)
established by the International Association of Diabetes in Pregnancy Study Groups (IADPSG).
RESEARCHDESIGNANDMETHODS — Thisarticlediscussesaretrospectivestudyof
8,711 women, delivering at 20 weeks’ gestation, who had a prenatal 2-h 75-g OGTT without
a prior 50-g challenge and were not treated with insulin, glyburide, diet, and/or exercise during
pregnancy. Associations between adverse outcomes and elevated OGTT values are reported.
RESULTS — After excluding treated women, 19.4% of the remaining women had IADPSG-
deﬁned GDM. Continuous fasting, 1- and 2-h OGTT measures, and GDM (yes/no) were signif-
icantlyassociatedwithmostadverseoutcomes.However,themagnitudeandsigniﬁcanceofrisk
for these outcomes differed by various combinations of abnormal glucose values. Women with
normal fasting and elevated postload values were at higher risk for preterm delivery, gestational
hypertension, and having an infant with hyperbilirubinema, whereas women with elevated
fasting and normal postload values were at higher risk of having a large-for-gestational-age
infant, compared with women without GDM.
CONCLUSIONS — Risks for different adverse outcomes vary depending on which single or
combined IADPSG-deﬁned OGTT thresholds are equaled or exceeded. Prospective studies are
needed to determine whether changing pre- and postprandial glucose targets during pregnancy
will more uniformly reduce adverse outcomes.
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G
estational diabetes mellitus (GDM)
is deﬁned as “any degree of glucose
intolerance with onset or ﬁrst rec-
ognition during pregnancy” (1). The di-
agnosis of GDM is typically based on the
results of a 2-h 75-g or 3-h 100-g oral
glucose tolerance test (OGTT), which
measuresmaternalfastingplasmaglucose
(FPG) and postload glucose concentra-
tions, administered between 24 and 28
weeks of gestation. American Diabetes
Association (ADA) guidelines confer a
GDM diagnosis if at least two 75-g or
100-g OGTT values meet the following
thresholds: 95 mg/dl FPG, 1-h glucose
180 mg/dl, 2-h glucose 155 mg/dl,
and 3-h glucose 140 mg/dl (2). These
thresholds were initially established to
identify women at high risk for type 2
diabetes following pregnancy (3).
GDMisassociatedwithincreasedrisk
for adverse maternal and perinatal out-
comes, such as macrosomia, shoulder
dystocia and birth injury, primary cesar-
ean delivery, preeclampsia, preterm de-
livery, and fetal and neonatal mortality
(4–7). However, risk for these outcomes
among women with modest hyperglyce-
mia during pregnancy has only recently
been studied. The Hyperglycemia and
Adverse Pregnancy Outcome (HAPO)
study investigated quantitative associa-
tions between maternal glycemia and ad-
verse outcomes and, after excluding
womenwithFPG105and/or2-h200
mg/dl, reported signiﬁcant associations
between increasing glucose and adverse
events, including birth weight 90th
percentile, preterm delivery, shoulder
dystocia/birth injury, primary cesarean
delivery, preeclampsia, and hyperbiliru-
binemia (8,9). These ﬁndings formed the
basis for the International Association of
Diabetes and Pregnancy Study Groups
(IADPSG) recommendations that GDM
be identiﬁed by at least one abnormal
75-g 2-h OGTT value: FPG 92 mg/dl,
1-hglucose180mg/dl,or2-hglu153
mg/dl (10).
Inthepresentstudy,weexaminedthe
association between each of the 75-g
OGTT glucose values (fasting, 1-h and
2-hglucose)andseveraladversematernal
and perinatal outcomes in untreated
women,takingintoaccountdifferencesin
maternal demographics, prepregnancy
BMI, and gestational weight gain. Addi-
tionally, we explored associations be-
tweenadverseoutcomesandcategoriesof
hyperglycemia that result in GDM diag-
nosis under IADPSG criteria to determine
whetherthelevelofriskissimilarforeach
abnormal OGTT result and combinations
thereof.
RESEARCH DESIGN AND
METHODS
Population and data sources
The Kaiser Permanente Southern Califor-
nia (KPSC) Medical Care Program is a
large, prepaid, group-practice, managed–
health care organization with 3.3 mil-
lion members in 2010. Members receive
their health care in KPSC-owned facilities
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the
1Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena,
California; and the
2Department of Obstetrics and Gynecology, Kaiser Permanente Bellﬂower Medical
Center, Bellﬂower, California.
Corresponding author: Jean M. Lawrence, jean.m.lawrence@kp.org.
Received 26 July 2010 and accepted 8 September 2010. Published ahead of print at http://care.
diabetesjournals.org on 15 September 2010. DOI: 10.2337/dc10-1445.
© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Clinical Care/Education/Nutrition/Psychosocial Research
ORIGINAL ARTICLE
2524 DIABETES CARE, VOLUME 33, NUMBER 12, DECEMBER 2010 care.diabetesjournals.orgthroughouttheseven-countyregion.This
study was approved by the KPSC Institu-
tional Review Board.
The study population consisted of
women who had a live singleton birth at
20 weeks’ gestation at the KPSC Bell-
ﬂowerMedicalCenterbetween1October
2005 and 31 March 2010, who under-
went a prenatal 2-h 75-g OGTT with no
prior 50-g oral glucose challenge test and
hadprepregnancyanddeliveryanthropo-
metric data (n  9,199). In this medical
center, routine clinical practice involved
treating women whose prenatal 75-g
OGTT results met at least two thresholds:
FPG 100 mg/dl, 1-h glucose 195 mg/
dl, and 2-h glucose 160 mg/dl with diet
and exercise therapy. Of these, women
whose FPG was consistently 105 mg/dl
or 1-h postprandial glucose was 140
mg/dl were treated with insulin or gly-
buride in addition to diet and exercise.
This practice is based on the analyses of
OGTT results and pregnancy outcomes
published by Sacks et al. (11). After ex-
cluding women who received any form of
treatment during pregnancy (n  488),
we used OGTT results to identify women
with GDM based on IADPSG guidelines
(10). For untreated women with more
than one OGTT during pregnancy, out-
comes are reported based on the test re-
sult within or nearest to 24–28 weeks’
gestation.Forwomenwithmorethanone
birth during the study period, only data
from the ﬁrst pregnancy were analyzed.
Maternal age at delivery, race/ethnicity
(Hispanic, non-Hispanic white, non-
Hispanic black, Asian/Paciﬁc Islander, and
other/multiple races), and parity (0, 1, and
2) were obtained from infant birth certif-
icates. Information on prenatal smoking
was obtained from the electronic health
record (EHR) during prenatal encounters.
Infant sex, gestational age at birth, birth
weight, and birth length were obtained
from the birth certiﬁcate or EHR. Ponderal
index was calculated as birth weight/
height
3 100 (12).
Categorization of OGTT results
Based on the results of the 2-h 75-g
OGTT, we categorized women into ﬁve
mutually exclusive categories: no glucose
impairment (no GDM), single isolated
impaired glucose tolerance (i-IGT1)i fe i -
ther 1-h glucose 180 mg/dl or 2-h glu-
cose 153 mg/dl and FPG 92 mg/dl,
isolatedimpairedfastingglucose(i-IFG)if
FPG 92 mg/dl and both 1-h glucose
180 mg/dl and 2-h glucose 153
mg/dl, double-isolated impaired glucose
tolerance (i-IGT2) if both 1-h glucose
180mg/dland2-hglucose153mg/dl
but FPG 92 mg/dl, and combined IFG
and IGT (IFGIGT) if FPG 92 mg/dl
and either 1-h glucose 180 mg/dl and/or
2-h glucose 153 mg/dl.
Measures of prepregnancy BMI and
gestational weight gain
Prepregnancy BMI and weight gain dur-
ing pregnancy both have been shown to
be associated with the development of
GDM (13–15) as well as adverse out-
comes independent of GDM (16–19).
Maternalprepregnancyweightandheight
were obtained from the EHR (n  7,894
[90.6%]) or from the infant’s birth certif-
icate if not available from the EHR (n 
817 [9.4%]). Among those with data
available from the EHR, identiﬁcation of
measured prepregnancy weight was con-
tingent upon the timing of the clinical
visit closest to last menstrual period
(LMP). To establish the LMP date, infant
gestational age at delivery (in days) was
subtracted from infant delivery date.
Heightandprepregnancyweightwerese-
lected hierarchically, if available, 0–3
months prior to LMP (n  3,046
[38.6%]), 0–3 months after LMP (n 
4,690 [59.4%]), or 3–6 months prior to
LMP (n  158 [2.0%]). Delivery weight
was obtained within 30 days prior to de-
livery; 96.1% were measured within 14
days of delivery. Prepregnancy BMI was
classiﬁed as normal (BMI 25 kg/m
2),
overweight (25  BMI  30 kg/m
2), or
obese (BMI 30 kg/m
2) (20). Gestational
weight gain was calculated as the differ-
ence between prepregnancy and delivery
weight. The 2009 Institute of Medicine
(IOM)guidelineswereusedtoclassifyex-
cessive weight gain during pregnancy
based on categories of prepregnancy BMI
(normal: 35 lb, overweight: 25 lb, or
obese: 20 lb) (21).
Maternal and infant outcomes
Large-for-gestational-age (LGA) infants
were deﬁned as sex-, race-, and gesta-
tional age–speciﬁc birth weight 90th
percentile. Consistent with the methods
usedbytheHAPOStudyGroup(11),per-
centiles for birth weight were determined
by quantile regression stratiﬁed by sex
and race/ethnicity, with adjustment for
gestational age and maternal parity. An
infant was considered to have a birth
weight 90th percentile if the birth
weight was greater than the estimated
90th percentile for the infant’s sex, gesta-
tional age, race/ethnicity, and maternal
parity. Delivery by primary cesarean sec-
tion was obtained from infant birth certif-
icates; data for women who had a
previous cesarean section (n  963) were
excluded from analysis of this outcome.
Preterm delivery was deﬁned as any de-
livery prior to 37 weeks of gestation. We
identiﬁed hyperbilirubinemia based on
ICD-9codes774.0–774.7withintheﬁrst
week of birth. Shoulder dystocia/birth in-
jury was deﬁned by ICD-9 codes 653.4,
653.5, 660.4, 767.0–767.9, or 959.0–
959.9 at delivery. We identiﬁed women
with gestational hypertensive disorders
by ICD-9 codes 642.3–642.6 and/or
642.9 during pregnancy. In analyses of
gestational hypertension, we excluded
women with pregestational hypertension
(ICD-9 codes 401–405.9, 642.0–642.2,
and/or 642.7; n  323).
Statistical analyses
Weexaminedtheassociationsbetweenma-
ternaldemographic,clinical,andanthropo-
metric characteristics; adverse clinical
outcomes; and GDM subtypes (i-IGT1, i-
IFG, i-IGT2, and IFGIGT). Associations
between categorical variables and GDM
subtype were assessed using
2tests; differ-
encesinmeancontinuousvariablesbysub-
type were evaluated using ANOVA with
Tukey honestly-signiﬁcant-difference ad-
justmentformultiplecomparisons.Pearson
product-moment correlations were used to
assessassociationsamongOGTTmeasures.
Multiple logistic regression models were
used to calculate adjusted odds ratios
(AORs) and corresponding 95% CIs for a
1-SDincreaseincontinuousfastingand1-h
and 2-h glucose levels associated with ad-
verse outcomes, after controlling for mater-
nalage,race/ethnicity,parity,prepregnancy
BMI, and gestational weight gain. AORs
were also calculated for the association be-
tween GDM and all adverse clinical out-
comes. All analyses were performed with
SAS version 9.1 (SAS Institute, Cary, NC).
RESULTS— The study population
consisted of 9,199 women, of which
2,179 (23.7%) met the IADPSG criteria
for GDM (10). After excluding 488
women who received any form of treat-
ment (5.3% of the population; 22.4% of
all women with GDM), the remaining
sample for this analysis was comprised of
8,711 untreated women with a mean age
of29.15.9years,themajorityofwhom
were Hispanic (Table 1). Among all
women, the mean prepregnancy BMI was
27.5  6.1 kg/m
2, which exceeds the
threshold for overweight, and the mean
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2526 DIABETES CARE, VOLUME 33, NUMBER 12, DECEMBER 2010 care.diabetesjournals.orgweeks of gestation at which OGTT was
performed was 26.7  2.9. Mean fasting
and 1-h and 2-h glucose levels were
83.4  7.9, 131.8  30.7, and 107.6 
23.0 mg/dl, respectively. Correlations
amongthesethreeglucosemeasureswere
0.39 for FPG and 1-h glucose, 0.30 for
FPG and 2-h glucose, and 0.62 for 1-h
and 2-h glucose (P  0.0001 for each
comparison).
Of these women, 1,691 (19.4%) had
IADPSG-deﬁned GDM. Compared with
women without GDM, those with GDM
tended to be slightly older, more parous,
havehighermeanprepregnancyBMI,and
have relatively similar mean gestational
weight gain (Table 1). Among women
with GDM, 52% were based on i-IFG,
23% on i-IGT1,5 %o ni-IGT2, and 20%
onIFGIGT.Of391womenwithi-IGT1,
131 (33.5%) had an abnormal 2-h glu-
cose value only (7.7% of all women with
GDM). Of those with IFGIGT (n 
331), only 55 had three abnormal OGTT
results (0.6% of GDM women), reﬂecting
the fact that women with the most abnor-
mal OGTT results were treated and there-
fore excluded from these analyses.
As shown in Table 1, women in the
i-IGT1 group had signiﬁcantly lower
prepregnancy BMI than those with i-IFG
or IFGIGT; BMI for these women was
similar to those with i-IGT2. On average,
weight gain for the i-IGT1 group was sim-
ilar to women of all other GDM subtypes.
Women with i-IFG had signiﬁcantly
higherprepregnancyBMIthanthosewith
i-IGT1 or i-IGT2; BMI was similar to those
with IFGIGT. Mean weight gain for
these women was similar to those with
i-IGT1, i-IGT2, or IFGIGT. Among all
GDM subtypes, prepregnancy BMI and
gestational weight gain were highest for
women with i-IFG and IFGIGT.
Glucose values and adverse
outcomes
Associations between adverse outcomes
and continuous fasting and 1-h and 2-h
glucose values, as well as glucose dichot-
omized at IADPSG cut points, are shown
in Table 2. Odds ratios for each continu-
ous glucose measure are expressed as risk
per 1-SD increase above the mean. Odds
ratios presented are adjusted for maternal
age, race/ethnicity, parity, prepregnancy
BMI, gestational weight gain, infant sex,
andgestationalageatOGTT.Resultswere
similar after additional adjustment for
maternal prenatal smoking. When mod-
eled separately, we found a signiﬁcant as-
sociation between each continuous
OGTT value and LGA, primary cesarean,
preterm delivery, and gestational hyper-
tension. We additionally observed signif-
icant associations between the
continuous1-hand2-hpostglucosechal-
lenge values and shoulder dystocia/birth
injury, as well as hyperbilirubinemia.
Odds ratios for signiﬁcant risk of adverse
outcomes categorized by IADPSG cut
points for each glucose measure were rel-
atively consistent with those of the con-
tinuous measures, except that those with
1-h glucose 180 mg/dl were not at sig-
niﬁcantly increased risk for primary ce-
sarean section or hyperbilirubinemia,
compared with women with 1-h glucose
180 mg/dl. Similarly, women with 2-h
glucose 153 mg/dl were not at signiﬁ-
cantly increased risk for LGA, shoulder
dystocia/birth injury, or hyperbiliru-
binemia, compared with those with 2-h
glucose153mg/dl.WomenwithGDM,
as deﬁned by IADPSG guidelines, were at
signiﬁcantly increased risk for all out-
comes except infant hyperbilirubinemia.
GDM subtypes and adverse
outcomes
Associations between GDM subtype (i-
IGT1, i-IFG, i-IGT2, and IFGIGT) and
each adverse outcome, adjusting for ma-
ternal age, race/ethnicity, parity, prepreg-
nancy BMI, and gestational weight gain
are presented in Table 3. We did not ob-
serve statistically signiﬁcant associations
between i-IGT1 and LGA, primary cesar-
ean, and shoulder dystocia/birth injury.
Women classiﬁed as having GDM based
on a single abnormal postload glucose
value were at signiﬁcantly increased risk
for preterm delivery, gestational hyper-
tension, and infant hyperbilirubinemia.
Conversely, women with i-IFG were
twiceaslikelytohaveanLGAinfant(95%
CI 1.62–2.45) and 45% more likely to
have shoulder dystocia/birth injury at de-
livery(1.05–2.00)thanthosewithnoglu-
cose impairment. Women with i-IFG
were also 29% more likely to have gesta-
tional hypertension (1.04–1.72) com-
pared with women without GDM.
Women with the i-IGT2 GDM subtype
were 2.33 times as likely to develop ges-
tational hypertension (1.20–4.51) than
women without GDM, and infants born
to these women were 2.85 times as likely
to be delivered preterm (1.59–5.10) than
infantsofmotherswithoutGDM.Women
with IFGIGT were more than twice as
likely to have gestational hypertension
(1.42–2.84), 87% more likely to have
shoulder dystocia/birth injury during de-
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likely to have an LGA infant (1.72–3.13)
than women without GDM.
LGA was more strongly associated
with GDM subtypes deﬁned by an abnor-
mal fasting glucose (i-IFG and IFGIGT)
than those based on abnormal postload
glucose values only. Additionally, while
riskforshoulderdystocia/birthinjurywas
elevated in all four GDM subtype groups,
the outcome was only signiﬁcantly asso-
ciated with i-IFG and IFGIGT. In con-
trast, preterm delivery, gestational
hypertension, and hyperbilirubinemia
appeared to be more strongly associated
with categories of GDM involving ele-
vated postload glucose (i-IGT1 and/or i-
IGT2).Infact,womenwithi-IGT2hadthe
highest risk for preterm delivery and ges-
tational hypertension among all GDM
subtypes.
CONCLUSIONS— In this sample of
8,711 untreated women, 19.4% of whom
had GDM by IADPSG criteria, we found a
signiﬁcant association between adverse
maternal and perinatal outcomes and in-
creasing fasting and 1- and 2-h OGTT
glucosevalues.Themagnitudeandsignif-
icance of these associations were consis-
tent with those reported by the HAPO
Study Group (8). As IADPSG guidelines
fordiagnosisofGDMweredeterminedby
the average glucose values in the HAPO
study, at which the adjusted risk for se-
lected adverse outcomes increased by
75% compared with the risk at mean glu-
cose levels overall, it was not surprising
that we additionally observed signiﬁcant
association between GDM status and all
adverseoutcomes,evenafteradjustingfor
confounders such as prepregnancy BMI
and gestational weight gain, which were
notincludedintheanalysesconductedby
the HAPO Study Group.
However, the formulation of the new
guidelines, whereby a single abnormal
fastingand1-hor2-hvalueissufﬁcientto
diagnose GDM, implies that each glucose
value contributes a signiﬁcant indepen-
dent effect on adverse outcomes and that
sucheffectsareequallyimportantforout-
come development. Models that examine
onlytheassociationsbetweenasingleglu-
cose measure and outcome, with or with-
out adjustment for multiple confounders,
do not account for the underlying corre-
lation between fasting and 1-h and 2-h
OGTT values. We observed signiﬁcant
correlations of moderate magnitude
among the three glucose measures (range
0.30–0.62)thatareconsistentwiththose
reported by HAPO investigators (8), sug-
gesting that a woman’s response to glu-
cose is at least partially associated with
her FPG levels. Therefore, we examined
variouscombinationsofabnormalvalues,
categorized women according to one of
four combinations that result in a diagno-
sis of GDM under IADPSG guidelines (i-
IGT1, i-IFG, i-IGT2, and IFGIGT) and
investigated group-speciﬁc risk for ad-
verse outcomes compared with women
without GDM.
Our results suggest that women with
i-IGT1 may have modestly elevated risk
for primary cesarean delivery, shoulder
dystocia/birth injury, or having an LGA
infant, compared with women without
GDM,buttheseriskswerenotstatistically
signiﬁcant. Most importantly, women di-
agnosed with GDM based on i-IFG may
have different risks for speciﬁc outcomes,
compared with women with GDM based
on abnormal 1-h and 2-h OGTT results.
For example, LGA and shoulder dystocia
appear to be more strongly associated
with categories of GDM based on abnor-
mal fasting values; the risk for LGA
amongthosewithelevatedfastingglucose
maybefurthercompoundedbyabnormal
postloadglucose.Incontrast,pretermde-
livery, gestational hypertension, and hy-
perbilirubinemia appear to be more
closely related to elevated postload glu-
cose than abnormal fasting values, with
the highest risks observed among women
with normal fasting and two elevated
postload glucose values.
We acknowledge several limitations
of this study. First, we observed consid-
erable variation in sample sizes for spe-
ciﬁc GDM subgroups, which is largely
attributed to the fact that women with the
most abnormal results were likely to be
treated and thus excluded from our anal-
yses. The smaller numbers of women in
i-IGT1 and i-IGT2 categories reduced our
power to detect statistically signiﬁcant
differences for some outcomes in these
groups.Additionally,giventhatdataused
for these analyses were collected during
thecourseofclinicalcare,therewassome
variability in the timing of ascertainment
of prepregnancy and delivery weight.
Among women with prepregnancy
weight extracted from the EHR, there was
littlevariabilityinthemeanprepregnancy
BMI by timing of measurement (mean
BMI  SD: 0–3 months prior to LMP
27.69  6.20 kg/m
2; 0–3 months after
LMP 27.69  6.14 kg/m
2; and 3–6
monthsbeforeLMP27.035.90kg/m
2).
Additionally, delivery weight was ascer-
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3.9% of the women with measurements
in the EHR (31.36  5.88 kg/m
2) and is
likely an underestimate of their true
weight at delivery (for women measured
within 2 weeks of delivery: 32.72  5.84
kg/m
2), as is delivery weight by self-
report (31.74  5.72 kg/m
2). Moreover,
we abstracted gestational age from the
EHR or infant birth certiﬁcate, which is
largely based on date of LMP rather than
estimates from ﬁrst or midtrimester ultra-
sound dates. This may have resulted in
some misclassiﬁcation of preterm deliv-
ery, which in turn may have inﬂuenced
our estimates of preterm delivery risk for
the various GDM subtypes. Lack of ultra-
sound data, as well as the lack of high-
quality information on maternal
behaviors and family history, precluded
us from controlling for additional con-
founders which may have affected some
outcomes.
The utilization of clinical and admin-
istrativeinformationallowedfortheiden-
tiﬁcation and characterization of women
with GDM based on standard laboratory
test (75-g 2-h OGTT) results, which al-
lowed us to disaggregate potential sub-
groups of GDM using OGTT values. In
addition, we were able to exclude women
who were treated with diet, exercise,
and/orpharmacotherapyforGDMduring
pregnancy, which provided an opportu-
nity to examine outcomes for untreated
women with modestly elevated glycemia.
This afforded us an opportunity to exam-
inetherelationshipbetweenglucosemea-
sures in untreated women, including
those who meet contemporary criteria for
GDM, and adverse clinical outcomes.
As more women with mild hypergly-
cemia will be diagnosed with GDM under
IADPSG criteria, examining this cohort
allowed us to assess outcomes for these
women if left untreated. Our data suggest
that the risks for different adverse mater-
nal and perinatal outcomes vary depend-
ing on which single or combined
IADPSG-deﬁned OGTT thresholds are
equaled or exceeded. Prospective studies
are needed to determine whether chang-
ing pre- and postprandial glucose targets
will more uniformly reduce adverse out-
comes for women whose pregnancies are
complicated by mild GDM.
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